TXG · 10X Genomics Inc
Price
Snapshot
50 fields · last close| Market Cap | $9.98B |
| P/E | — |
| Float | 115.0M |
| Beta | 2.04 |
| Volatility | 50.9% |
| Exchange | NASDAQ |
| Sector | Life Sciences Tools & Services |
| Cap tier | Mid cap |
| Macro sensitivity | Very High |
| Clavix score | 52 |
| Price | 78.57 |
| Change | +2.57% |
| Prev Close | 76.60 |
| Open | 77.64 |
| Day Low | 75.21 |
| Day High | 78.08 |
| Avg Vol | 3 |
| Avg $ Vol | $216.5M |
| 52W High | 79.94 |
| 52W Low | 11.16 |
| 52W Pos | 98.0% |
| From High | −1.71% |
| From Low | +604.03% |
| Max DD 1Y | −28.03% |
| Spread | 0.10% |
| Liquidity | Normal |
| SMA 20 | +17.90% |
| SMA 50 | +38.64% |
| SMA 200 | +150.80% |
| RSI (14) | 73.7 |
| Vol 30D | 71.6% |
| Vol 90D | 70.9% |
| 1Y Range | 11–80 |
| Daily bars | 516 |
| Perf Week | +11.68% |
| Perf Month | +23.17% |
| Perf Quarter | +120.40% |
| Perf Half Y | +316.76% |
| Perf Year | +495.65% |
| Perf YTD | +372.74% |
| Prev Day | +2.57% |
| Clavix | C- |
| Debt / Eq | 0.00 |
| Curr Ratio | 4.46 |
| Int Cover | -66.1× |
| FCF Margin | 19.5% |
| Rev Growth | −12.7% |
| Profit | Unprofitable |
| Leverage | Low |
| Sector rank | 18 / 19 |
Clavix risk grade
regraded every trading dayTXG grades C-, 52 of 100. Steadiest on News Sentiment (70), most exposed on Price Stability (35, fragile). 2 of the 4 weighted dimensions sit above the Life Sciences Tools & Services median. Ranks 18 of 19 in Life Sciences Tools & Services by Clavix score.
How rough the ride is
| TXG | Life Sciences Tools & Services median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 2.04 | 1.18 |
| Volatilityannualized | 50.9% | 29.6% |
| Max drawdown, past yearworst peak-to-trough fall | −28.0% | — |
| Typical daily movemedian absolute daily change | 2.80% | — |
| Days beyond ±3%of the last 252 sessions | 11847% | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| TXG | Life Sciences Tools & Services median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 2.04 | 1.18 |
| Macro sensitivityrate, dollar and credit exposure bucket | Very High | Moderate47% of 19 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Life Sciences Tools & Services names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| TXG | |
|---|---|
| 1 week | +11.7% |
| 1 month | +23.2% |
| Year to date | +372.7% |
| 1 year | +495.6% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| TXG | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30since 30 Jul |
| Average score0 most bearish, 100 most bullish | 59 |
| Bullish · bearisharticles above 60 · below 40 | 16 · 4 |
| Directionarticles whose tone is improving vs worsening | 16 ↑ 4 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 19 Life Sciences Tools & Services names Clavix covers; the tick is the sector median.
Growth
| TXG | |
|---|---|
| Revenue growthyear over year | −12.7% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Life Sciences Tools & Services median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Recent news
most recent scored articles · the chip is the article’s score · click to openShares of 10x Genomics (TXG) hit a new 52-week high during Wednesday's trading session after UBS Group raised their price target on the stock from $20.00 to $68.00. UBS maintained a neutral rating on the stock, and it traded as high as $67.00. The article body is truncated and ends mid-sentence, so further details were not provided.
Lunit announced that 10x Genomics (Nasdaq: TXG) will incorporate Lunit's AI-powered pathology platform, Lunit SCOPE IO, into its oncology biomarker discovery workflow, pairing TXG's spatial biology tools with AI-based H&E (a standard tissue-staining method used in pathology) image analysis.
Director John Stuelpnagel sold 20,000 shares of 10x Genomics on September 3rd at an average price of $61.75, totaling about $1.235 million, reducing his stake by 5.74%. After the sale, he still owns 328,436 shares worth roughly $20.28 million.
Royal Bank of Canada upgraded 10x Genomics (TXG) to a 'hold' rating, meaning analysts neither recommend buying nor selling. Separately, Zacks Research had already moved TXG from 'strong-buy' to 'hold' on May 18th.
Royal Bank of Canada upgraded its rating on 10x Genomics to "hold" in a report released on Tuesday. No other details were provided.
Nearest peers by size
Life Sciences Tools & Services| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| RGEN | Repligen Corp | B- | $9.98B | 240.33 | 1.14 | Compare |
| AVTR | Avantor Inc | B- | $10.50B | — | 0.97 | Compare |
| BRKR | Bruker Corp | C | $9.35B | — | 1.25 | Compare |
| QGEN | Qiagen NV | B+ | $8.93B | 21.82 | 0.60 | Compare |
| TECH | Bio-Techne Corp | B | $11.35B | 62.40 | 1.30 | Compare |
| CRL | Charles River Laboratories International Inc | B- | $13.27B | — | 1.41 | Compare |
| TEM | Tempus AI Inc | D- | $14.05B | — | 2.33 | Compare |
| RVTY | Revvity Inc | B | $16.01B | 67.38 | 1.09 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. Three months free on iPhone.